Drugs / tibremciclib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05316259 | Apr → Aug 2022 | — | Betta Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03791112 | Jul 2019 → Dec 2025 overdue | cancer | Betta Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05433480 | May 2022 → Dec 2023 | breast cancer | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tibremciclib | “Tibremciclib (BPI-16350) is a novel potent selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6).” PMID 40403388 ↗ May 2025 |
| Known as | BPI-16350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05316259 ↗ |
| Action | Inhibit | “novel potent selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6)” PMID 40403388 ↗ May 2025 |
| Modality | Small molecule | — CHEMBL5314545 ↗ |
| Route | Oral | “BPI-16350 capsules administered orally” NCT03791112 ↗ |
| Target | CDK4 | “novel potent selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6)” PMID 40403388 ↗ May 2025 |